Skip to main content
Top
Published in: Endocrine 2/2015

01-06-2015 | Research Letter

Hypogonadotropic hypogonadism in a female patient previously diagnosed as having waardenburg syndrome due to a sox10 mutation

Authors: Yoko Izumi, Ikuma Musha, Erina Suzuki, Manami Iso, Tomoko Jinno, Reiko Horikawa, Shin Amemiya, Tsutomu Ogata, Maki Fukami, Akira Ohtake

Published in: Endocrine | Issue 2/2015

Login to get access

Excerpt

Hypogonadotropic hypogonadism (HH) is a clinically and genetically heterogeneous condition that can be associated with several additional clinical features such as anosmia, cleft palate, and hearing loss [1]. HH with anosmia is referred to as Kallmann syndrome (KS). More than 20 genes are known to underlie HH and/or KS, although mutations in these genes account for only a minor portion of the etiology of HH/KS [14]. In 2013, Pingault et al. identified SOX10 mutations in seven patients with KS [5]. Furthermore, Pingault et al. found that genetic knockout of Sox10 disrupted migration of GnRH cells in murine fetuses [5]. Subsequently, Vaaralahti et al. identified an additional KS patient with a SOX10 mutation [6]. These results indicate that SOX10 mutations constitute rare genetic causes of KS. Currently, SOX10 is known as one of the causative genes of Waardenburg syndrome (WS), a rare genetic disorder characterized by hearing loss and hypopigmentation in the skin, hair, and eye [7]. Indeed, hearing impairment with or without gray/white hair was found in most of the KS cases reported by Pingault et al. and Vaaralahti et al. [5, 6]. However, detailed clinical assessment of the SOX10 mutation-positive patients and functional assays of the SOX10 mutants remain fragmentary. Thus, genetic links between HH/KS and WS have not been fully established. Here, we performed molecular and clinical analyses of a previously reported patient with WS due to a frameshift mutation in SOX10. …
Appendix
Available only for authorised users
Literature
1.
go back to reference R. Rapaport, Disorders of the gonads, in Nelson textbook of pediatrics, 18th edn., ed. by R.M. Kliegman, R.E. Behrman, H.B. Jenson, B.F. Stanton (Saunders, Philadelphia, 2007), pp. 2374–2403 R. Rapaport, Disorders of the gonads, in Nelson textbook of pediatrics, 18th edn., ed. by R.M. Kliegman, R.E. Behrman, H.B. Jenson, B.F. Stanton (Saunders, Philadelphia, 2007), pp. 2374–2403
2.
3.
go back to reference H. Miraoui, A.A. Dwyer, G.P. Sykiotis, L. Plummer, W. Chung, B. Feng, A. Beenken, J. Clarke, T.H. Pers, P. Dworzynski, K. Keefe, M. Niedziela, T. Raivio, W.F.Jr Crowley, S.B. Seminara, R. Quinton, V.A. Hughes, P. Kumanov, J. Young, M.A. Yialamas, J.E. Hall, G.V. Vliet, J.P. Chanoine, J. Rubenstein, M. Mohammadi, P.S. Tsai, Y. Sidis, K. Lage, N. Pitteloud, Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am. J. Hum. Genet. 92(5), 725–743 (2013)CrossRefPubMedCentralPubMed H. Miraoui, A.A. Dwyer, G.P. Sykiotis, L. Plummer, W. Chung, B. Feng, A. Beenken, J. Clarke, T.H. Pers, P. Dworzynski, K. Keefe, M. Niedziela, T. Raivio, W.F.Jr Crowley, S.B. Seminara, R. Quinton, V.A. Hughes, P. Kumanov, J. Young, M.A. Yialamas, J.E. Hall, G.V. Vliet, J.P. Chanoine, J. Rubenstein, M. Mohammadi, P.S. Tsai, Y. Sidis, K. Lage, N. Pitteloud, Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am. J. Hum. Genet. 92(5), 725–743 (2013)CrossRefPubMedCentralPubMed
4.
go back to reference Y. Izumi, E. Suzuki, S. Kanzaki, S. Yatsuga, S. Kinjo, M. Igarashi, T. Maruyama, S. Sano, R. Horikawa, N. Sato, K. Nakabayashi, K. Hata, A. Umezawa, T. Ogata, Y. Yoshimura, M. Fukami, Genome-wide copy number analysis and systematic mutation screening in 58 patients with hypogonadotropic hypogonadism. Fertil. Steril. (2014). doi:10.1016/j.fertnstert.2014.06.017 PubMed Y. Izumi, E. Suzuki, S. Kanzaki, S. Yatsuga, S. Kinjo, M. Igarashi, T. Maruyama, S. Sano, R. Horikawa, N. Sato, K. Nakabayashi, K. Hata, A. Umezawa, T. Ogata, Y. Yoshimura, M. Fukami, Genome-wide copy number analysis and systematic mutation screening in 58 patients with hypogonadotropic hypogonadism. Fertil. Steril. (2014). doi:10.​1016/​j.​fertnstert.​2014.​06.​017 PubMed
5.
go back to reference V. Pingault, V. Bodereau, V. Baral, S. Marcos, Y. Watanabe, A. Chaoui, C. Fouveaut, C. Leroy, O. Vérier-Mine, C. Francannet, D. Dupin-Deguine, F. Archambeaud, F.J. Kurtz, J. Young, J. Bertherat, S. Marlin, M. Goossens, J.P. Hardelin, C. Dodé, N. Bondurand, Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am. J. Hum. Genet. 92(5), 707–724 (2013)CrossRefPubMedCentralPubMed V. Pingault, V. Bodereau, V. Baral, S. Marcos, Y. Watanabe, A. Chaoui, C. Fouveaut, C. Leroy, O. Vérier-Mine, C. Francannet, D. Dupin-Deguine, F. Archambeaud, F.J. Kurtz, J. Young, J. Bertherat, S. Marlin, M. Goossens, J.P. Hardelin, C. Dodé, N. Bondurand, Loss-of-function mutations in SOX10 cause Kallmann syndrome with deafness. Am. J. Hum. Genet. 92(5), 707–724 (2013)CrossRefPubMedCentralPubMed
6.
go back to reference K. Vaaralahti, J. Tommiska, V. Tillmann, N. Liivak, J. Känsäkoski, E.M. Laitinen, T. Raivio, De novo SOX10 nonsense mutation in a patient with Kallmann syndrome and hearing loss. Pediatr. Res. (2014). doi:10.1038/pr.2014.60 K. Vaaralahti, J. Tommiska, V. Tillmann, N. Liivak, J. Känsäkoski, E.M. Laitinen, T. Raivio, De novo SOX10 nonsense mutation in a patient with Kallmann syndrome and hearing loss. Pediatr. Res. (2014). doi:10.​1038/​pr.​2014.​60
7.
go back to reference V. Pingault, D. Ente, F. Dastot-Le Moal, M. Goossens, S. Marlin, N. Bondurand, Review and update of mutations causing Waardenburg syndrome. Hum. Mutat. 31(4), 391–406 (2010)CrossRefPubMed V. Pingault, D. Ente, F. Dastot-Le Moal, M. Goossens, S. Marlin, N. Bondurand, Review and update of mutations causing Waardenburg syndrome. Hum. Mutat. 31(4), 391–406 (2010)CrossRefPubMed
8.
go back to reference M. Iso, M. Fukami, R. Horikawa, N. Azuma, N. Kawashiro, T. Ogata, SOX10 mutation in Waardenburg syndrome type II. Am. J. Med. Genet. A. 146A(16), 2162–2163 (2008)CrossRefPubMed M. Iso, M. Fukami, R. Horikawa, N. Azuma, N. Kawashiro, T. Ogata, SOX10 mutation in Waardenburg syndrome type II. Am. J. Med. Genet. A. 146A(16), 2162–2163 (2008)CrossRefPubMed
9.
go back to reference M. Furukawa, M. Kamide, T. Miwa, R. Umeda, Significance of intravenous olfaction test using thiamine propyldisulfide (Alinamin) in olfactometry. Auris Nasus Larynx 15(1), 25–31 (1988)PubMed M. Furukawa, M. Kamide, T. Miwa, R. Umeda, Significance of intravenous olfaction test using thiamine propyldisulfide (Alinamin) in olfactometry. Auris Nasus Larynx 15(1), 25–31 (1988)PubMed
10.
go back to reference T. Tanaka: Endocrine examination. In: T. Tanaka (ed.) New pocket guide of clinical standard values for children. 1st ed., 106-132. Jihou, Tokyo, (2009) [In Japanese] T. Tanaka: Endocrine examination. In: T. Tanaka (ed.) New pocket guide of clinical standard values for children. 1st ed., 106-132. Jihou, Tokyo, (2009) [In Japanese]
11.
go back to reference H. Inada, T. Imamura, R. Nakajima: Assessment of pituitary function. In; H. Inada, T. Imamura, R. Nakajima (eds.) Manual of endocrine examinations of children. 2nd ed., 5-22. Medical Review, Osaka, (2002) [In Japanese] H. Inada, T. Imamura, R. Nakajima: Assessment of pituitary function. In; H. Inada, T. Imamura, R. Nakajima (eds.) Manual of endocrine examinations of children. 2nd ed., 5-22. Medical Review, Osaka, (2002) [In Japanese]
12.
go back to reference N. Bondurand, V. Pingault, D.E. Goerich, N. Lemort, E. Sock, C.L. Caignec, M. Wegner, M. Goossens, Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum. Mol. Genet. 9(13), 1907–1917 (2000)CrossRefPubMed N. Bondurand, V. Pingault, D.E. Goerich, N. Lemort, E. Sock, C.L. Caignec, M. Wegner, M. Goossens, Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum. Mol. Genet. 9(13), 1907–1917 (2000)CrossRefPubMed
13.
go back to reference H. Zhang, H. Chen, H. Luo, J. An, L. Sun, L. Mei, C. He, L. Jiang, W. Jiang, K. Xia, J.D. Li, Y. Feng, Functional analysis of Waardenburg syndrome-associated PAX3 and SOX10 mutations: report of a dominant-negative SOX10 mutation in Waardenburg syndrome type II. Hum. Genet. 131(3), 491–503 (2012)CrossRefPubMed H. Zhang, H. Chen, H. Luo, J. An, L. Sun, L. Mei, C. He, L. Jiang, W. Jiang, K. Xia, J.D. Li, Y. Feng, Functional analysis of Waardenburg syndrome-associated PAX3 and SOX10 mutations: report of a dominant-negative SOX10 mutation in Waardenburg syndrome type II. Hum. Genet. 131(3), 491–503 (2012)CrossRefPubMed
14.
go back to reference B. Jelena, L. Christina, V. Eric, Q.R. Fabiola, Phenotypic variability in Waardenburg syndrome resulting from a 22q12.3-q13.1 microdeletion involving SOX10. Am. J. Med. Genet A. 164(6), 1512–1519 (2014)CrossRef B. Jelena, L. Christina, V. Eric, Q.R. Fabiola, Phenotypic variability in Waardenburg syndrome resulting from a 22q12.3-q13.1 microdeletion involving SOX10. Am. J. Med. Genet A. 164(6), 1512–1519 (2014)CrossRef
15.
go back to reference E. Fisher, P. Scambler, Human haploinsufficiency-one for sorrow, two for joy. Nat. Genet. 7(1), 5–7 (1994)CrossRefPubMed E. Fisher, P. Scambler, Human haploinsufficiency-one for sorrow, two for joy. Nat. Genet. 7(1), 5–7 (1994)CrossRefPubMed
Metadata
Title
Hypogonadotropic hypogonadism in a female patient previously diagnosed as having waardenburg syndrome due to a sox10 mutation
Authors
Yoko Izumi
Ikuma Musha
Erina Suzuki
Manami Iso
Tomoko Jinno
Reiko Horikawa
Shin Amemiya
Tsutomu Ogata
Maki Fukami
Akira Ohtake
Publication date
01-06-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0434-4

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine